Stryker (NYSE:SYK) Given New $290.00 Price Target at TD Cowen

Stryker (NYSE:SYK) had its price target decreased by TD Cowen from $298.00 to $290.00 in a report published on Friday,Benzinga reports. TD Cowen currently has a hold rating on the medical technology company’s stock.

A number of other equities research analysts have also recently weighed in on SYK. Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. Johnson Rice lowered shares of Stryker to a “hold” rating in a research report on Friday. BMO Capital Markets reissued an “outperform” rating and set a $309.00 target price on shares of Stryker in a research note on Friday. Evercore set a $350.00 price target on shares of Stryker in a research report on Monday, July 6th. Finally, UBS Group began coverage on shares of Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target for the company. Sixteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $355.84.

Stryker Stock Performance

Shares of NYSE SYK opened at $291.56 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock has a 50 day simple moving average of $292.83 and a 200-day simple moving average of $324.51. The company has a market cap of $111.83 billion, a PE ratio of 31.05, a P/E/G ratio of 2.01 and a beta of 0.78. Stryker has a 12-month low of $267.00 and a 12-month high of $389.33.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.83% and a net margin of 13.78%. The business had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same period last year, the company earned $3.19 earnings per share. The business’s quarterly revenue was up 7.6% compared to the same quarter last year. On average, equities research analysts forecast that Stryker will post 14.93 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 over the last three months. Company insiders own 4.60% of the company’s stock.

Institutional Trading of Stryker

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp increased its position in shares of Stryker by 1.2% during the second quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after purchasing an additional 183,400 shares during the period. Wellington Management Group LLP lifted its position in Stryker by 0.6% in the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares during the period. Bank of America Corp DE bought a new position in Stryker in the second quarter worth $1,404,284,000. Royal Bank of Canada boosted its stake in Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Stryker by 21.8% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after buying an additional 481,175 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.